Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Tuberculosis

Free Subscription Articles published in J Antimicrob Chemother Retrieve available abstracts of 49 articles: HTML format

Single Articles

May 2020
1. KADURA S, King N, Nakhoul M, Zhu H, et al
   Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
   J Antimicrob Chemother. 2020 May 3. pii: 5828363. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2020
2. YOSHIDA S, Iwamoto T, Arikawa K, Sekizuka T, et al
   Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient.
   J Antimicrob Chemother. 2020 Apr 17. pii: 5821489. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2020
3. VAN RIE A, Whitfield MG, De Vos E, Scott L, et al
   Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact.
   J Antimicrob Chemother. 2020 Feb 4. pii: 5722231. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2019
4. MEHTA K, Ravimohan S, Pasipanodya JG, Srivastava S, et al
   Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.
   J Antimicrob Chemother. 2019 Jul 4. pii: 5528382. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. PI R, Liu Q, Jiang Q, Gao Q, et al
   Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS.
   J Antimicrob Chemother. 2019;74:1795-1798.
   PubMed     Abstract available
   
   
   May 2019
6. JAJOU R, van der Laan T, de Zwaan R, Kamst M, et al
   WGS more accurately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing.
   J Antimicrob Chemother. 2019 May 22. pii: 5497435. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. YUSTE JR, Serrano-Alonso M, Carmona-Torre F, Del Pozo JL, et al
   Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis.
   J Antimicrob Chemother. 2019 May 18. pii: 5491490. doi: 10.1093.
   PubMed    
   
   
   February 2019
8. FARHAT MR, Sixsmith J, Calderon R, Hicks ND, et al
   Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.
   J Antimicrob Chemother. 2019 Feb 21. pii: 5359497. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. HU Y, Pertinez H, Liu Y, Davies G, et al
   Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure.
   J Antimicrob Chemother. 2019 Feb 20. pii: 5353164. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2019
10. CHIREHWA MT, McIlleron H, Wiesner L, Affolabi D, et al
    Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    J Antimicrob Chemother. 2019;74:139-148.
    PubMed     Abstract available
    
    
    
11. VON BRAUN A, Castelnuovo B, Ledergerber B, Cusato J, et al
    High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
    J Antimicrob Chemother. 2019;74:135-138.
    PubMed     Abstract available
    
    
    December 2018
12. AKKERMAN OW, Alffenaar JWC
    Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
    J Antimicrob Chemother. 2018 Dec 1. pii: 5224542. doi: 10.1093.
    PubMed    
    
    
    October 2018
13. LOPEZ B, Siqueira de Oliveira R, Pinhata JMW, Chimara E, et al
    Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region.
    J Antimicrob Chemother. 2018 Oct 25. pii: 5144701. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. DOAN TN, Fox GJ, Meehan MT, Scott N, et al
    Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    J Antimicrob Chemother. 2018 Oct 5. pii: 5116208. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2018
15. WHITFIELD MG, Warren RM, Mathys V, Scott L, et al
    The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.
    J Antimicrob Chemother. 2018 Jul 5. pii: 5049577. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2018
16. CANEZIN PH, Caleffi-Ferracioli KR, Scodro RBL, Siqueira VLD, et al
    Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure.
    J Antimicrob Chemother. 2018 Mar 22. pii: 4951545. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. ASHLEY EA, Recht J, Chua A, Dance D, et al
    An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000.
    J Antimicrob Chemother. 2018 Mar 5. pii: 4921008. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2018
18. HEINRICHS MT, Vashakidze S, Nikolaishvili K, Sabulua I, et al
    Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.
    J Antimicrob Chemother. 2018;73:477-483.
    PubMed     Abstract available
    
    
    
19. MOK J, Kang H, Hwang SH, Park JS, et al
    Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    J Antimicrob Chemother. 2018;73:503-508.
    PubMed     Abstract available
    
    
    January 2018
20. DOOKIE N, Rambaran S, Padayatchi N, Mahomed S, et al
    Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.
    J Antimicrob Chemother. 2018 Jan 19. pii: 4817621. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2017
21. LIU Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, et al
    Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    J Antimicrob Chemother. 2017 Dec 12. pii: 4735127. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2017
22. VYAZOVAYA A, Levina K, Zhuravlev V, Viiklepp P, et al
    Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context.
    J Antimicrob Chemother. 2017 Oct 30. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. YEW WW, Liang D, Chan DP, Shi W, et al
    Molecular mechanisms of clofazimine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017;72:2943-2944.
    PubMed    
    
    
    September 2017
24. CHEN J, Zhang S, Cui P, Shi W, et al
    Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Sep 12. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2017
25. SVENSSON RJ, Gillespie SH, Simonsson USH
    Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.
    J Antimicrob Chemother. 2017;72:2311-2319.
    PubMed     Abstract available
    
    
    June 2017
26. KAUSHIK A, Ammerman NC, Tasneen R, Story-Roller E, et al
    In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.
    J Antimicrob Chemother. 2017 Jun 1. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. YEW WW, Leung CC, Zhang Y
    Oxidative stress and TB outcomes in patients with diabetes mellitus?
    J Antimicrob Chemother. 2017;72:1552-1555.
    PubMed     Abstract available
    
    
    May 2017
28. MAITRE T, Petitjean G, Chauffour A, Bernard C, et al
    Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
    J Antimicrob Chemother. 2017 May 23. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. NAIDOO A, Chirehwa M, McIlleron H, Naidoo K, et al
    Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    J Antimicrob Chemother. 2017;72:1441-1449.
    PubMed     Abstract available
    
    
    April 2017
30. ZIMENKOV DV, Nosova EY, Kulagina EV, Antonova OV, et al
    Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
    J Antimicrob Chemother. 2017 Apr 6. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. SEKAGGYA-WILTSHIRE C, von Braun A, Scherrer AU, Manabe YC, et al
    Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
    J Antimicrob Chemother. 2017;72:1172-1177.
    PubMed     Abstract available
    
    
    March 2017
32. GURUMURTHY M, Verma R, Naftalin CM, Hee KH, et al
    Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
    J Antimicrob Chemother. 2017 Mar 18. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. JAGANATH D, Schaaf HS, Donald PR
    Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
    J Antimicrob Chemother. 2017 Mar 9. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. VILLELLAS C, Coeck N, Meehan CJ, Lounis N, et al
    Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    J Antimicrob Chemother. 2017;72:684-690.
    PubMed     Abstract available
    
    
    February 2017
35. CAVANAUGH JS, Jou R, Wu MH, Dalton T, et al
    Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    J Antimicrob Chemother. 2017 Feb 20. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. CHOLO MC, Mothiba MT, Fourie B, Anderson R, et al
    Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.
    J Antimicrob Chemother. 2017;72:338-353.
    PubMed     Abstract available
    
    
    January 2017
37. GOTHAM D, Fortunak J, Pozniak A, Khoo S, et al
    Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    J Antimicrob Chemother. 2017 Jan 10. pii: dkw522. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2016
38. ROBERTSON GT, Scherman MS, Bruhn DF, Liu J, et al
    Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw467. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. NAGU TJ, Aboud S, Matee MI, Maeurer MJ, et al
    Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
    J Antimicrob Chemother. 2016 Dec 20. pii: dkw503. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2016
40. AMMERMAN NC, Swanson RV, Tapley A, Moodley C, et al
    Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.
    J Antimicrob Chemother. 2016.
    PubMed     Abstract available
    
    
    September 2016
41. HOFFMANN H, Borroni E, Schena E, Nedialkova L, et al
    Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system-authors' response.
    J Antimicrob Chemother. 2016.
    PubMed    
    
    
    June 2016
42. DUTTA NK, Bruiners N, Pinn ML, Zimmerman MD, et al
    Statin adjunctive therapy shortens the duration of TB treatment in mice.
    J Antimicrob Chemother. 2016;71:1570-7.
    PubMed     Abstract available
    
    
    May 2016
43. HENNIG S, Svensson EM, Niebecker R, Fourie PB, et al
    Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
    J Antimicrob Chemother. 2016;71:1330-40.
    PubMed     Abstract available
    
    
    
44. COJUTTI P, Duranti S, Isola M, Baraldo M, et al
    Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
    J Antimicrob Chemother. 2016;71:1323-9.
    PubMed     Abstract available
    
    
    April 2016
45. PANDIE M, Wiesner L, McIlleron H, Hughes J, et al
    Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    J Antimicrob Chemother. 2016;71:1037-40.
    PubMed     Abstract available
    
    
    
46. OLARU ID, Lange C, Heyckendorf J
    Personalized medicine for patients with MDR-TB.
    J Antimicrob Chemother. 2016;71:852-5.
    PubMed     Abstract available
    
    
    March 2016
47. SAKTIAWATI AM, Sturkenboom MG, Stienstra Y, Subronto YW, et al
    Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    J Antimicrob Chemother. 2016;71:703-10.
    PubMed     Abstract available
    
    
    
48. RIEU R, Chang C, Collin SM, Fazekas J, et al
    Time to detection in liquid culture of sputum in pulmonary MDR-TB does not predict culture conversion for early discharge.
    J Antimicrob Chemother. 2016;71:803-6.
    PubMed     Abstract available
    
    
    February 2016
49. RIGOUTS L, Coeck N, Gumusboga M, de Rijk WB, et al
    Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
    J Antimicrob Chemother. 2016;71:314-23.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: